LOGIN  |  REGISTER
Chimerix
C4 Therapeutics

NEXGEL to Participate in the LD Micro Main Event XVI on October 3rd

September 26, 2023 | Last Trade: US$2.36 0.03 -1.26

LANGHORNE, Pa., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, CEO, will participate in the LD Micro Main Event XVI being held on October 3rd – 5th in Los Angeles.

LD Micro Main Event XVI

Date: October 3, 2023

Presentation Time: 12:00 P.M. PT

Registration: HERE

If you would like to book 1x1 investor meetings with NEXGEL, please contact your LD Micro representative or send an email to This email address is being protected from spambots. You need JavaScript enabled to view it..

About NEXGEL, INC.

NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page